Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daledalin
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
01
Overview
Daledalin is a synthetic small molecule antidepressant developed in the early 1970s. It acts as a selective norepinephrine reuptake inhibitor (NRI), with no significant effects on serotonin or dopamine reuptake, and lacks antihistamine or anticholinergic properties. Daledalin was investigated for the treatment of depression but was never marketed. The compound features an indoline backbone and is chemically described as methyl[3-(3-methyl-1-phenyl-2,3-dihydro-1H-indol-3-yl)propyl]amine. It may also exhibit monoamine oxidase inhibitory activity in vitro, likely by acting as a substrate[1][2][5][7].
- Other names
- daledalindaledalinadaledaline
02
Targets
NET (Norepinephrine Transporter)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on daledalin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daledalin.